Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
National Cancer Center Hospital East · Leipzig University · +15 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
688
total citations
- FWCI
- 79.72
- Percentile
- 100%
- References
- 25
Citations per year
Authors
20Topics & keywords
Topics
Keywords
- Medicine
- Internal medicine
- Clinical endpoint
- Regimen
- Gastroenterology
- Cancer
- Phases of clinical research
- Oxaliplatin
UN Sustainable Development Goals
- Partnerships for the goals
No related works found for this paper.